



Cover image: Regulation of fibroblast attachment by interleukin (IL)-1-mediated loss of cartilage damage. Healthy articular cartilage (right) provides no substrate for healthy wt fibroblasts and also hTNFtg synovial fibroblasts (SFs) show only limited attachment to intact cartilage. The loss of proteoglycans as induced by IL-1 (left) greatly facilitates the attachment of SFs, particularly of hTNFtg fibroblasts. This attachment to as yet undefined proteoglycans or proteoglycan fragments is mediated also by syndecan-4 because the loss of syndecan-4 decreases the attachment of SFs to IL-1-treated cartilage. p 1010.

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WCH 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.082

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2012 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Buxton Press, Buxton

Annals of the Rheumatic Diseases (ISSN: 0003-4967) is published monthly by BMJ Publishing Group and is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorials

- 791** The risks of smoking in patients with spondyloarthritis
J Braun, J Sieper, A Zink
- 793** Progression of joint damage despite control of inflammation in rheumatoid arthritis: a role for cartilage damage driven synovial fibroblast activity
F PJG Laféber WH Van der Laan

Viewpoint

- 796** Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?
M A González-Gay, C González-Juanatey, J Ilorca

Review

- 799** After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
R J Wakefield, M A D'Agostino, E Naredo, M H Buch, A Iagnocco, L Terslev, M Ostergaard, M Backhaus, W Grassi, M Dougados, G R Burmester, B Saleem, E de Miguel, C Estrach, K Ikeda, M Gutierrez, R Thompson, P Balint, P Emery

Clinical and epidemiological research

- 804** Smoking and risk of incident psoriatic arthritis in US women
W Li, J Han, A A Qureshi
- 809** Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort
H Y Chung, P Machado, D van der Heijde, M A D'Agostino, M Dougados
- 817** Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
Y Tanaka, M Harigai, T Takeuchi, H Yamanaka, N Ishiguro, K Yamamoto, N Miyasaka, T Koike, M Kanazawa, T Oba, T Yoshinari, D Baker, and the GO-FORTH Study Group
- 825** Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden
L Årlestig, M Mullazehi, H Kokkonen, J Rocklöv, J Rönnelid, S R Dahlqvist
- 830** Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet
M F Bakker, J WG Jacobs, A A Kruijze, M J van der Veen, C van Booma-Frankfort, S A Vreugdenhil, J WJ Bijlsma, F PJG Laféber, P MJ Welsing
- 836** The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review
C Bombardier, M Barbieri, A Parthan, D J Zack, V Walker, D Macarios, J S Smolen
- 845** A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry
L G Schipper, M Vermeer, H H Kuper, M O Hoekstra, C J Haagsma, A A Den Broeder, P van Riel, J Fransen, M AFJ van de Laar
- 851** Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP
M L Hetland, M Ostergaard, B Ejlberg, S Jacobsen, K Stengaard-Pedersen, P Junker, T Lottenburger, I Hansen, L S Andersen, U Tarp, A Svendsen, J K Pedersen, H Skjold, T Ellingsen, H Lindegaard, J Pedenphant, K Hørslev-Petersen, C MESTRA study group
- 857** Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
E C Keystone, J M Kremer, A Russell, J Box, C Abud-Mendoza, M G Elizondo, A Luo, R Aranda, I Delaet, R Swainink, S Gujrathi, M Luggen
- 862** Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis
C I Daïen, Y Duny, T Baretche, J-P Daurès, B Combe, J Morel
- 869** The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
L K Mercer, A C Green, J B Galloway, R Davies, M Lunt, W G Dixon, K D Watson, British Society for Rheumatology Biologics Register Control Centre Consortium, D PM Symmons, K L Hyrich, on behalf of the British Society for Rheumatology Biologics Register*
- 875** Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
A Ruysen-Witrand, S Rouanet, B Combe, M Dougados, X L Loët, J Sibilia, J Tebib, X Mariette, A Constantin

MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



When you have finished with this please recycle it

- 878** Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study
J Braun, X Baraliakos, K-G A Hermann, D van der Heijde, R D Inman, A A Deodhar, A Baratele, S Xu, W Xu, B Hsu
- 885** Association between the IL-1 family gene cluster and spondyloarthritis
D Monnet, A Kadi, B Izac, N Lebrun, F Letourneur, E Zinovieva, R Said-Nahal, G Chiochia, M Breban
- 891** Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification
G Verbruggen, R Wittoek, B V Cruyssen, D Elewaut
- 899** Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis
I K Haugen, P Bøyesen, B Slatkowsky-Christensen, S Sesseng, D van der Heijde, T K Kvien
- 905** Development of radiological knee osteoarthritis in patients with knee complaints
B M de Klerk, S Willemsen, D Schiphof, J B J van Meurs, B W Koes, A Hofman, S M A Bierma-Zeinstra
- 911** A mindfulness-based group intervention to reduce psychological distress and fatigue in patients with inflammatory rheumatic joint diseases: a randomised controlled trial
H A Zangi, P Mowinckel, A Finset, L R Eriksson, T O Hoystad, A K Lunde, K B Hagen
- 918** Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy
A Spinillo, F Beneventi, V Ramoni, R Caporali, E Locatelli, M Simonetta, C Cavagnoli, C Alpini, G Albonico, E Prisco, C Montecucco
- 924** Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study
G G Teng, L-W Ang, K G Saag, M C Yu, J-M Yuan, W-P Koh
- 929** Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial
N Dalbeth, R Ames, G D Gamble, A Horne, S Wong, B Kuhn-Sherlock, A MacGibbon, F M McQueen, I R Reid, K Palmarno
- 935** Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial
M Spaeth, R M Bennett, B A Benson, Y G Wang, C Lai, E H Choy
- 943** Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica
Baerlecken N T, Linnemann A, Gross W L, Moosig F, Vazquez-Rodriguez T R, Gonzalez-Gay M A, Martin J, Kötter I, Henes J C, Melchers I, Vaith P, Schmidt R E, Witte T
- 948** Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study
M W Heijstek, P G M van Gageldonk, G A M Berbers, N M Wulfraat
- 955** Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
L Harper, M D Morgan, M Walsh, P Hoglund, K Westman, O Flossmann, V Tesar, P Vanhille, K de Groot, R Luqmani, L F Flores-Suarez, R Watts, C Pusey, A Bruchfeld, N Rasmussen, D Blockmans, C O Savage, D Jayne on behalf of EUVAS investigators
- 961** Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study
H Chinoy, S Adimulam, F Marriage, P New, M Vincze, E Zilahi, A Kapićány, A Gyetvai, L Ekholm, P Novota, M Remakova, P Charles, N J McHugh, L Padyukov, L Alfredsson, J Vencovsky, I E Lundberg, K Danko, W E Ollier, R G Cooper
- 966** Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis
S Arends, C Grootsholten, R HWM Derksen, S P Berger, R GL de Sévaux, A E Voskuyl, M Bijl, J HM Berden, on behalf of the Dutch Working Party on systemic lupus erythematosus
- 974** The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis
D Holzinger, M Frosch, A Kastrop, F H M Prince, M H Otten, L W A Van Suijlekom-Smit, R ten Cate, E P A H Hoppenreijts, S Hansmann, H Moncrieffe, S Ursu, L R Wedderburn, J Roth, D Foell, H Wittkowski
- 981** Association between genetic variants in the tumour necrosis factor/lymphotoxin α /lymphotoxin β locus and primary Sjögren's syndrome in Scandinavian samples
A I Bolstad, S L Hellard, G Kristjansdottir, L Vasaitis, M Kvamström, C Sjöwall, S J A Johnsen, P Eriksson, R Omdal, J G Brun, M Wahren-Herlenius, E Theander, A-C Syvänen, L Rönnblom, G Nordmark, R Jonsson
- 989** Combination etanercept and methotrexate provides better disease control in very early (≤ 4 months) versus early rheumatoid arthritis (> 4 months and < 2 years): post hoc analyses from the COMET study
P Emery, T K Kvien, B Combe, B Freundlich, D Robertson, T Ferdousi, E Bananis, R Pedersen, A S Koenig
- 993** Anti-TIF1 γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays
M Labrador-Horrillo, M A Martínez, A Selva-O'Callaghan, E Trallero-Araguás, E Balada, M Vilardeell-Tarrés, C Juárez
- 997** Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
S M D Pan, A Scherer, C Gabay, A Finckh
- 1000** Endogenous parathyroid hormone is associated with reduced cartilage volume in vivo in a population-based sample of adult women
S L Brennan, F M Cicuttini, G C Nicholson, J A Pasco, M A Kotowicz, A E Wluka

Basic and translational research

- 1004** Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis
A Korb-Pap, A Stratis, K Mühlberg, B Niederreiter, S Hayer, F Echermeier, R Stange, J Zwerina, T Pap, H Pavenstädt, G Schett, J S Smolen, K Redlich
- 1012** Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1 β and inhibited by peroxisome proliferator activated receptor α agonist
S Clockaerts, Y M Bastiaansen-Jenniskens, C Feijt, L De Clerck, J A N Verhaar, A-M Zuurmond, V Stojanovic-Susulic, J Somville, M Kloppenburg, G J V M van Osch
- 1019** Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
C Beyer, N Reich, S C Schindler, A Akhmetshina, C Dees, M Tomcik, C Hirth-Dietrich, G von Degenfeld, P Sandner, O Distler, G Schett, J H W Distler
- 1027** Increased interleukin (IL)-7R α expression in salivary glands of patients with primary Sjögren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity
A Bikker, A A Kruijs, M Wenting, M A Vernel, J W J Bijlsma, F P J G Lafèber, J A G van Roon
- 1034** Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis
M Manetti, Y Allanore, M Saad, C Fatini, V Coghignac, S Guiducci, E Romano, P Airò, P Caramaschi, I Tinazzi, V Ricciari, A D Rossa, R Abbate, R Caporali, G Cuomo, G Valesini, P Dieudé, E Hachulla, J-L Cracowski, K Tiev, L Letenneur, P Amouyel, J-C Lambert, G Chiochia, M Martinez, L Ibba-Manneschi, M Matucci-Cerinic

- 1042** A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype
A-M Malfait, A B Seymour, F Gao, M D Tortorella, M-P H L Graverand-Gastineau, L S Wood, M Doherty, S Doherty, W Zhang, N K Arden, F L Vaughn, P E Leaverton, T D Spector, D J Hart, R A Maciewicz, K R Muir, R Das, R E Sorge, S G Sotocinal, A Schorsch-Petcu, A M Valdes, J S Mogil
- 1049** PAR₂ expression in peripheral blood monocytes of patients with rheumatoid arthritis
A Crilly, E Burns, M B Nickedel, J C Lockhart, M E Perry, P W Ferrell, D Baxter, J Dale, L Dunning, H Wilson, J S Nijjar, J A Gracie, W R Ferrell, I B McInnes
- 1055** Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis
M Zong, I Loell, E Lindroos, G A Nader, H Alexanderson, C S Hallengren, K Borg, S Amardottir, I B McInnes, I E Lundberg
- 1064** Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage
M Manetti, S Guiducci, E Romano, S Bellando-Randone, M L Conforti, L Ibbia-Manneschi, M Matucci-Cerinic
- 1073** MicroRNA-199a* regulates the expression of cyclooxygenase-2 in human chondrocytes
N Akhtar, T M Haqqi
- 1081** The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis
G Krönke, N Reich, C Scholtysek, A Akhmetshina, S Uderhardt, P Zerr, K Palumbo, V Lang, C Dees, O Distler, G Schett, J H W Distler
- 1088** Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease
P L Klarenbeek, M J H de Hair, M E Doorenspleet, B D C van Schaik, R E E Esveldt, M G H van de Sande, T Cantaert, D M Gerlag, D Baeten, A H C van Kampen, F Baas, P P Tak, N de Vries

Letters

- 1094** *Campylobacter fetus* infection in three rheumatoid arthritis patients treated with rituximab
A Meyer, A Theulin, E Chatelus, X Argemi, C Sordet, R M Javier, Y Hansmann, J Sibilia, J-E Gottenberg
- 1095** Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01
C Terao, K Ikari, K Ohmura, T Suzuki, T Iwamoto, K Takasugi, H Saji, A Taniguchi, S Momohara, H Yamanaka, F Matsuda, T Mimori
- 1097** Patients with early arthritis who fulfil the 1987 ACR classification criteria for rheumatoid arthritis but not the 2010 ACR/EULAR criteria
S J Jung, S-W Lee, Y J Ha, K-H Lee, Y Kang, M-C Park, S-K Lee, Y-B Park
- 1098** Anakinra treatment of SAPHO syndrome: short-term results of an open study
D Wendling, C Prati, F Aubin
- 1100** Elevated active secretory sphingomyelinase in antineutrophil cytoplasmic antibody-associated primary systemic vasculitis
A P Kiprianos, M D Morgan, M A Little, L Harper, P A Bacon, S P Young
- 1102** A population-based study on the association between rheumatoid arthritis and erectile dysfunction
J J Keller, H-C Lin
- 1103** ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis
M Dougados, J Braun, R B Vargas, L Gossec, W Maksymowych, J Sieper, D van der Heijde

Miscellaneous

- 1106** Corrections